Related Experiment Videos
Itraconazole therapy in pityriasis versicolor
The British Journal of Dermatology
|August 1, 1986
Summary
Itraconazole effectively treated pityriasis versicolor in an open trial. Most patients achieved healing with two different short-course regimens, showing good efficacy for this fungal infection.
Area of Science:
- Dermatology
- Mycology
- Clinical Pharmacology
Background:
- Pityriasis versicolor is a superficial fungal infection caused by Malassezia species.
- Disseminated lesions require effective antifungal treatment.
Purpose of the Study:
- To evaluate the efficacy of itraconazole in treating disseminated pityriasis versicolor.
- To compare two different dosing regimens of itraconazole.
Main Methods:
- Open trial involving 30 patients with confirmed pityriasis versicolor.
- Randomized allocation to either 200 mg daily for 5 days or 100 mg daily for 10 days.
- Assessment of treatment outcomes 3 weeks post-therapy.
Main Results:
- 25 out of 30 patients (83.3%) achieved complete healing.
- Two patients had mild residual lesions, two had considerable residual lesions, and one relapsed.
- Adverse events were mild, including dyspepsia and transient elevation of liver enzymes (GOT, GPT).
Conclusions:
- Itraconazole demonstrates high efficacy in treating disseminated pityriasis versicolor.
- Both tested regimens are effective with a favorable safety profile.
- Short-course itraconazole therapy is a viable option for pityriasis versicolor.